Immune and cell therapy in type 1 diabetes: too little too late?

Bibliography

• Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 1992;8:209-27
   PubMed Web of Science ®Google Scholar
• Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15:516-42
   PubMed Web of Science ®Google Scholar
• Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man–macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 1991;165:97-103
   PubMed Web of Science ®Google Scholar
• Jahromi MM, Eisenbarth GS. Cellular and molecular pathogenesis of type 1A diabetes. Cell Mol Life Sci 2007;64:865-72
   PubMed Web of Science ®Google Scholar
• Weets I, De Leeuw IH, Du Caju MV, The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 2002;25:840-6
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS. Prediction of type 1 diabetes: the natural history of the prediabetic period. Adv Exp Med Biol 2004;552:268-90
   PubMed Web of Science ®Google Scholar
• Decochez K, Truyen I, van der Auwera B, Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005;48:687-94
   PubMed Web of Science ®Google Scholar
• Decochez K, De Leeuw IH, Keymeulen B, IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia 2002;45:1658-66
   PubMed Web of Science ®Google Scholar
• Vandemeulebroucke E, Keymeulen B, Decochez K, Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 2010;53:36-44
   PubMed Web of Science ®Google Scholar
• Xu P, Wu Y, Zhu Y, Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care 2010;33:2508-13
   PubMed Web of Science ®Google Scholar
• Sosenko JM, Palmer JP, Greenbaum CJ, Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-9
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial – Type 1. Diabetes Care 2005;28:1068-76
   PubMed Web of Science ®Google Scholar
• Nanto-Salonen K, Kupila A, Simell S, Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-455
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Trial – Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91
   PubMed Web of Science ®Google Scholar
• Vandemeulebroucke E, Gorus FK, Decochez K, Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab 2009;35:319-27
   PubMedGoogle Scholar
• Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31
   PubMed Web of Science ®Google Scholar
• Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007;148:17-31
   PubMed Web of Science ®Google Scholar
• Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus, Beseda, MD: ClinicalTrials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00419562?term=NCT00419562&rank=1 [Last accessed 10 February 2011]
   Google Scholar
• Raz I, Eldor R, Naparstek Y. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol 2005;23:128-34
   PubMed Web of Science ®Google Scholar
• Hanninen A, Hamilton-Williams E, Kurts C. Development of new strategies to prevent type 1 diabetes: the role of animal models. Ann Med 2003;35:546-63
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-7
   PubMed Web of Science ®Google Scholar
• Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005;48:1247-57
   PubMed Web of Science ®Google Scholar
• Feutren G, Papoz L, Assan R, Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986;2:119-24
   PubMed Web of Science ®Google Scholar
• Assan R, Feutren G, Sirmai J, Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 1990;39:768-74
   PubMed Web of Science ®Google Scholar
• Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International kidney biopsy registry of cyclosporine in autoimmune diseases. N Engl J Med 1992;326:1654-60
   PubMed Web of Science ®Google Scholar
• Silverstein J, Maclaren N, Riley W, Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319:599-604
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-54
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608
   PubMed Web of Science ®Google Scholar
• Pipeleers D, Chintinne M, Denys B, Restoring a functional beta-cell mass in diabetes. Diabetes Obes Metab 2008;10(Suppl 4):54-62
   PubMedGoogle Scholar
• Keymeulen B, Walter M, Mathieu C, Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614-23
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Candon S, Fafi-Kremer S, Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010;115:1145-55
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T, Zumsteg U, Reimers J, Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993;5:185-91
   PubMed Web of Science ®Google Scholar
• Held W, MacDonald HR, Weissman IL, Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 1990;87:2239-43
   PubMed Web of Science ®Google Scholar
• Mastrandrea L, Yu J, Behrens T, Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-9
   PubMed Web of Science ®Google Scholar
• Ban L, Zhang J, Wang L, Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci USA 2008;105(36):13644-9
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5:219-26
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52
   PubMed Web of Science ®Google Scholar
• Gottlieb PA, Quinlan S, Krause-Steinrauf H, Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care 2010;33:826-32
   PubMed Web of Science ®Google Scholar
• Voltarelli JC, Couri CE, Stracieri AB, Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-76
   PubMed Web of Science ®Google Scholar
• Couri CE, Oliveira MC, Stracieri AB, C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301:1573-9
   PubMed Web of Science ®Google Scholar
• van Etten E, Dardenne O, Gysemans C, 1,25-Dihydroxyvitamin D3 alters the profile of bone marrow-derived dendritic cells of NOD mice. Ann NY Acad Sci 2004;1037:186-92
   PubMed Web of Science ®Google Scholar
• van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101
   PubMed Web of Science ®Google Scholar
• Unger WW, Laban S, Kleijwegt FS, Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009;39:3147-59
   PubMed Web of Science ®Google Scholar
• Gearon CL, Hussain MJ, Vergani D, Peakman M. Lymphocyte vaccination protects prediabetic non-obese diabetic mice from developing diabetes mellitus. Diabetologia 1997;40:1388-95
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M, GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20
   PubMed Web of Science ®Google Scholar
• Protege encore study- clinical trial of teplizumab (MGA031) in children and adults with recent-onset type 1 diabetes mellitus. Beseda, MD: ClinicalTrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00920582?term=NCT00920582&rank=1 [Last accessed 10 February 2011]
   Google Scholar
• Subcutaneous administration of teplizumab in adults with type 1 diabetes (SUBCUE). ClinicalTrials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01189422?term=NCT01189422&rank=1 [Last accessed 10 February 2011]
   Google Scholar
• Keymeulen B, Gillard P, Mathieu C, Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA 2006;103:17444-9
   PubMed Web of Science ®Google Scholar
• Gillard P, Ling Z, Mathieu C, Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 2008;85:256-63
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Ling Z, Gorus FK, Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998;41:452-9
   PubMed Web of Science ®Google Scholar
• Vantyghem MC, Kerr-Conte J, Arnalsteen L, Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 2009;32:1473-8
   PubMed Web of Science ®Google Scholar
• Shapiro AM, Ricordi C, Hering BJ, International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-30
   PubMed Web of Science ®Google Scholar
• Shapiro AM, Lakey JR, Ryan EA, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8
   PubMed Web of Science ®Google Scholar
• Froud T, Ricordi C, Baidal DA, Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005;5:2037-46
   PubMed Web of Science ®Google Scholar
• Bellin MD, Kandaswamy R, Parkey J, Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008;8:2463-70
   PubMedGoogle Scholar
• Markmann JF, Deng S, Huang X, Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003;237:741-9; discussion 749-750
   PubMed Web of Science ®Google Scholar
• Gangemi A, Salehi P, Hatipoglu B, Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008;8:1250-61
   PubMedGoogle Scholar
• Benhamou PY, Oberholzer J, Toso C, Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d'Ilots de Langerhans. Diabetologia 2001;44:859-64
   PubMed Web of Science ®Google Scholar
• Luzi L, Perseghin G, Brendel MD, Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 2001;50:277-82
   PubMed Web of Science ®Google Scholar
• Warnock GL, Thompson DM, Meloche RM, A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008;86:1762-6
   PubMed Web of Science ®Google Scholar
• Venturini M, Angeli E, Maffi P, Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology 2005;234:617-24
   PubMed Web of Science ®Google Scholar
• Maleux G, Gillard P, Keymeulen B, Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. J Vasc Interv Radiol 2005;16:1693-7
   PubMed Web of Science ®Google Scholar
• Movahedi B, Keymeulen B, Lauwers MH, Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. Transpl Int 2003;16:186-90
   PubMed Web of Science ®Google Scholar
• Secchi A, Socci C, Maffi P, Islet transplantation in IDDM patients. Diabetologia 1997;40:225-31
   PubMed Web of Science ®Google Scholar
• Hering BJ, Kandaswamy R, Ansite JD, Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-5
   PubMed Web of Science ®Google Scholar
• Hering BJ, Kandaswamy R, Harmon JV, Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004;4:390-401
   PubMed Web of Science ®Google Scholar
• Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-58
   PubMed Web of Science ®Google Scholar
• Evgenov NV, Medarova Z, Dai G, In vivo imaging of islet transplantation. Nat Med 2006;12:144-8
   PubMed Web of Science ®Google Scholar
• Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med 2007;356:2754-5
   PubMed Web of Science ®Google Scholar
• Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med 2010;363:1289-90
   Google Scholar
• Utzschneider KM, Prigeon RL, Tong J, Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia 2007;50:2516-25
   PubMed Web of Science ®Google Scholar
• Gjessing HJ, Reinholdt B, Faber OK, Pedersen O. The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1991;124:556-62
   PubMedGoogle Scholar
• Chen CC, Chen RH, Chang CT, Cheah N. Reproducibility of the first-phase insulin release in the intravenous glucose tolerance test. J Formos Med Assoc 1996;95:639-41
   PubMed Web of Science ®Google Scholar
• Ganda OP, Day JL, Soeldner JS, Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes 1978;27:715-25
   PubMed Web of Science ®Google Scholar
• Ryan EA, Lakey JR, Paty BW, Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002;51:2148-57
   PubMed Web of Science ®Google Scholar
• Ryan EA, Lakey JR, Rajotte RV, Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001;50:710-9
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
   PubMed Web of Science ®Google Scholar
• Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26:605-10
   PubMed Web of Science ®Google Scholar
• Ryan EA, Paty BW, Senior PA, Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9
   PubMed Web of Science ®Google Scholar
• Dufrane D, Gianello P. Pig islet xenotransplantation into non-human primate model. Transplantation 2008;86:753-60
   PubMed Web of Science ®Google Scholar
• Phelps CJ, Koike C, Vaught TD, Production of alpha1,3-galactosyltransferase-deficient pigs. Science 2003;299:411-4
   PubMed Web of Science ®Google Scholar
• Heneine W, Tibell A, Switzer WM, No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998;352:695-9
   PubMed Web of Science ®Google Scholar
• Open-label investigation of the safety and effectiveness of DIABECELL(R) in patients with type I diabetes mellitus ClinicalTrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00940173?term=NCT00940173&rank=1 [Last accessed 10 February 2011]
   Google Scholar
• Assady S, Maor G, Amit M, Insulin production by human embryonic stem cells. Diabetes 2001;50:1691-7
   PubMed Web of Science ®Google Scholar
• Segev H, Fishman B, Ziskind A, Differentiation of human embryonic stem cells into insulin-producing clusters. Stem Cells 2004;22:265-74
   PubMed Web of Science ®Google Scholar
• Blyszczuk P, Czyz J, Kania G, Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci USA 2003;100:998-1003
   PubMed Web of Science ®Google Scholar
• Rajagopal J, Anderson WJ, Kume S, Insulin staining of ES cell progeny from insulin uptake. Science 2003;299:363
   PubMed Web of Science ®Google Scholar
• Kroon E, Martinson LA, Kadoya K, Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008;26:443-52
   PubMed Web of Science ®Google Scholar
• Sipione S, Eshpeter A, Lyon JG, Insulin expressing cells from differentiated embryonic stem cells are not beta cells. Diabetologia 2004;47:499-508
   PubMed Web of Science ®Google Scholar
• Holland AM, Gonez LJ, Harrison LC. Progenitor cells in the adult pancreas. Diabetes Metab Res Rev 2004;20:13-27
   PubMed Web of Science ®Google Scholar
• Bonner-Weir S, Inada A, Yatoh S, Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. Biochem Soc Trans 2008;36:353-6
   PubMed Web of Science ®Google Scholar
• Xu X, D'Hoker J, Stange G, beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 2008;132:197-207
   PubMed Web of Science ®Google Scholar
• Meier JJ, Bhushan A, Butler PC. The potential for stem cell therapy in diabetes. Pediatr Res 2006;59:65R-73R
   PubMed Web of Science ®Google Scholar
• Ritzel RA, Butler PC. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 2003;52:1701-8
   PubMed Web of Science ®Google Scholar
• Cheung AT, Dayanandan B, Lewis JT, Glucose-dependent insulin release from genetically engineered K cells. Science 2000;290:1959-62
   PubMed Web of Science ®Google Scholar
• Lee HC, Kim SJ, Kim KS, Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000;408:483-8
   PubMed Web of Science ®Google Scholar
• Pipeleers D, In't Veld P, Pipeleers-Marichal M, Gorus F. The beta cell population in type 1 diabetes. Novartis Found Symp 2008;292:19-24; discussion 24-31, 122-129, 202-203
   PubMedGoogle Scholar
• Bonner-Weir S, Li WC, Ouziel-Yahalom L, beta-cell growth and regeneration: replication is only part of the story. Diabetes 2010;59:2340-8
   PubMed Web of Science ®Google Scholar
• Roep BO, Stobbe I, Duinkerken G, Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48:484-90
   PubMed Web of Science ®Google Scholar
• Huurman VA, Hilbrands R, Pinkse GG, Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008;3:e2435
   PubMed Web of Science ®Google Scholar
• Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes 1989;38(Suppl 1):85-7
   PubMedGoogle Scholar
• Monti P, Scirpoli M, Maffi P, Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008;118:1806-14
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Al Bakir I, Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol 2010;50:1238-48
   PubMed Web of Science ®Google Scholar
• Cernea S, Raz I, Herold KC, Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009;25:694-704
   PubMed Web of Science ®Google Scholar
• Waldmann H. Tolerance: an overview and perspectives. Nat Rev Nephrol 2010;6:569-76
   PubMed Web of Science ®Google Scholar
• Hilbrands R, Huurman VA, Gillard P, Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009;58:2267-76
   PubMed Web of Science ®Google Scholar
• Orive G, Hernandez RM, Gascon AR, Cell encapsulation: promise and progress. Nat Med 2003;9:104-7
   PubMed Web of Science ®Google Scholar